Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

KEAP1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	durvalumab Resistant: B - Late Trials durvalumab Resistant : B	durvalumab Resistant: B - Late Trials durvalumab Resistant : B
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
KEAP1 mutation	Solid Tumor	KEAP1 mutation	Solid Tumor	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2
KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
KEAP1 mutation	Lung Cancer	KEAP1 mutation	Lung Cancer	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2	IPN60090 Sensitive: C2 – Inclusion Criteria IPN60090 Sensitive : C2
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3
KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3
KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KEAP1 mutation	Lung Adenocarcinoma	KEAP1 mutation	Lung Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KEAP1 mutation	Lung Adenocarcinoma	KEAP1 mutation	Lung Adenocarcinoma	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials pembrolizumab + ramucirumab Sensitive : C3	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials pembrolizumab + ramucirumab Sensitive : C3
KEAP1 mutation	Lung Adenocarcinoma	KEAP1 mutation	Lung Adenocarcinoma	DRP-104 Sensitive: D – Preclinical DRP-104 Sensitive : D	DRP-104 Sensitive: D – Preclinical DRP-104 Sensitive : D